BioSpace News Archive

Boehringer Ingelheim and Zealand Pharma A/S announced additional data demonstrating superior efficacy with survodutide versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.

Kane Biotech Inc., announces that it has issued 9,703,809 restricted share units of the Company to various directors, officers, employees and consultants of the Company pursuant to the second amended and restated performance and restricted share unit plan of the Company dated May 23, 2023.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata.

Findings from SURMOUNT-2, a study of tirzepatide in participants with type 2 diabetes who have obesity were announced, demonstrating more weight loss in individuals with diabetes than any other medication to date.

New research from the National Institutes of Health found that blood glucose levels obtained at childhood examinations predicted future diabetes related complications such as kidney disease and eye disease.

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd. for rare diseases within the contractually agreed time frame.

Sagimet Biosciences Inc. announced an oral presentation of data from the planned interim analysis of a prespecified subset of patients at week 26 of the Phase 2b FASCINATE-2 clinical trial of denifanstat, an investigational fatty acid synthase inhibitor, in nonalcoholic steatohepatitis patients with moderate to advanced fibrosis, stages F2 or F3, as confirmed by liver biopsy.

RELIEF THERAPEUTICS Holding SA and the World Orphan Drug Alliance announced an exclusive, long-term distribution agreement between Relief Therapeutics’ subsidiary APR Applied Pharma Research SA and WODA’s member company Vector Pharma FZCO to introduce PKU GOLIKE Plus®3-16 in the Middle East.

Molecure S.A. announces that it has filed an Investigational New Drug application with the U.S. FDA for OATD-01, a first in class and potentially disease modifying Chitotriosidase inhibitor.

Intercept Pharmaceuticals, Inc. announced new results from a planned interim analysis of its ongoing Phase 2 study 747-213 assessing improvements in serum biomarkers of hepatic function, cholestasis and inflammation in patients with primary biliary cholangitis after treatment with an investigational combination of obeticholic acid and bezafibrate.